AHA opposes any further delay of 340B drug ceiling price rule

Sep 20, 2017 - 02:45 PM

The AHA today urged the Health Resources and Services Administration to implement its final rule on 340B drug ceiling prices and civil monetary penalties for manufacturers without delay. “Delaying the implementation of the ceiling price and CMPs an additional nine months – from Oct. 1, 2017 to July 1, 2018 – is not justified given the exhaustive development process that has occurred,” wrote AHA Executive Vice President Tom Nickels. AHA also reiterated its support for HRSA’s decision to codify its “penny pricing policy” to strengthen oversight of 340B ceiling prices and discourage manufacturers from raising prices faster than inflation. “While this policy has been in place for many years, drug manufacturers have not applied it consistently,” AHA said. “…In addition, we look forward to working with HRSA on further guidance on the 340B ceiling reporting system and how 340B hospitals and covered entities can access ceiling price information to establish instances of manufacturer overcharges.”

Related News Articles

Headline
Appeals court upholds lower court denial of AbbVie’s preliminary injunction, preserving Mississippi 340B contract pharmacy law
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…
Perspective
Hospital Outpatient Departments Are Different from Independent Physician Offices
Public
Every health care provider strives to deliver their patients the best possible care, but not all providers offer the same level or complexity of care. Current…
Headline
Study: MA beneficiaries’ hospital stays longer than those under Traditional Medicare
A JAMA internal medicine study published Sept. 8 found that since the COVID-19 pandemic, Medicare Advantage beneficiaries have been experiencing longer…
Headline
AHA urges FTC, DOJ to investigate anticompetitive activity by drug companies on 340B rebate models 
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts…
Headline
Study finds less than 40% of Medicare beneficiaries with OUD receive standard care
A Health Affairs study published Sept. 2 found that less than 40% of Medicare beneficiaries with opioid use disorder received standard care in alignment with…
Headline
AHA study finds HOPDs treat sicker patients than independent physician offices
The AHA Sept. 3 released a study conducted by KNG Health Consulting that found Medicare patients who receive care in a hospital outpatient department are more…